Description

Contact hours available until 4/30/2020.

Requirements for Successful Completion:
Complete the learning activity in its entirety and complete the online CNE evaluation.

Nephrology Nursing Journal Editorial Board Statements of Disclosure:
In accordance with ANCC governing rules Nephrology Nursing Journal Editorial Board statements of disclosure are published with each CNE offering. The statements of disclosure for this offering are published below.

Paula Dutka, MSN, RN, CNN, disclosed that she is a coordinator of Clinical Trials for the following sponsors: Amgen, Rockwell Medical, Keryx Biopharmaceuticals, Akebia Therapeutics, and Dynavax Technologies.

Norma J. Gomez, MBA, MSN, CNNe, disclosed that she is a member of the ZS Pharma Advisory Council.

Tamara M. Kear, PhD, RN, CNS, CNN, disclosed that she is a member of the ANNA Board of Directors, serves on the Scientific Advisory Board for Kibow Biotech, Inc., and is employed by Fresenius Kidney Care as an acute hemodialysis RN.

All other members of the Editorial Board had no actual or potential conflict of interest in relation to this continuing nursing education activity.

This article was reviewed and formatted for contact hour credit by Beth Ulrich, EdD, RN, FACHE, FAAN, Nephrology Nursing Journal Editor, and Sally Russell, MN, CMSRN, CPP, ANNA Education Director.

Commercial Support and Sponsorship:
No commercial support or sponsorship declared.

Accreditation Statement:
American Nephrology Nurses Association – Provider is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

ANNA is a provider approved by the California Board of Registered Nursing, provider number CEP 00910.

This CNE article meets the Nephrology Nursing Certification Commission’s (NNCC’s) continuing nursing education requirements for certification and recertification.

Learning Engagement Activity:
For more information about this topic, please see the session entitled, “Transplantation ~ Novel Immunosuppressive Protocols for Kidney Transplantation and Treatment of Rejection,” presented by Nicole S. Ejaz, in ANNA’s Online Library - Click Here! (Additional costs may be associated)

Learning Outcome:
After completing this learning activity, the learner will be able to describe how poor immunosuppressive medication adherence prevalence results in costly, undesirable patient outcomes; discuss how cognitive (education, attitude, beliefs) and behavioral medication adherence interventions have proven largely ineffective for those with chronic illnesses, including adult kidney transplant recipients; evaluate an innovative six-month SystemCHANGE intervention followed by a six-month maintenance phase study designed to enhance immunosuppressive medication adherence improved medication adherence in older adult participant; and analyze how both medication taking and timing were markedly improved in this case resulting in clinically meaningful results.

Author(s)

• Cynthia L. Russell, PhD, RN, FAAN , Professor and Associate Dean for Distributive Programs, University of Tennessee Health Science Cente
• Courtney Miller, BSN, RN
• Laura M. Remy, BSN, RN, MPH
• Jennifer L. Wessol, PhD(c), BSN, RN
• Angela M. Andrews, PhD, RN-BC, CNE
• Dana Aholt, MSN, RN, CNN
• Debra Clark, RN
• Karen Hardinger, PharmD, BCPS
• Tara O’Brien, PhD, RN, CNE
• Donna K. Hathaway, PhD, FAAN
• Kathy Goggin, PhD